Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Ainos Inc (AIMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: AIMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -80.86% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.48M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.22 | 52 Weeks Range 0.40 - 2.60 | Updated Date 06/29/2025 |
52 Weeks Range 0.40 - 2.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2978.02% |
Management Effectiveness
Return on Assets (TTM) -30.93% | Return on Equity (TTM) -82.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 61772226 | Price to Sales(TTM) 98.68 |
Enterprise Value 61772226 | Price to Sales(TTM) 98.68 | ||
Enterprise Value to Revenue 581.62 | Enterprise Value to EBITDA -1.6 | Shares Outstanding 20960200 | Shares Floating 9206027 |
Shares Outstanding 20960200 | Shares Floating 9206027 | ||
Percent Insiders 65.58 | Percent Institutions 0.55 |
Upturn AI SWOT
Ainos Inc
Company Overview
History and Background
Ainos Inc., formerly known as SG Blocks, Inc., focuses on developing and commercializing therapeutics to treat immune disorders and viral infections, with a focus on RNA activating immunotherapeutics. Founded in 2007.
Core Business Areas
- Pharmaceuticals: Development and commercialization of pharmaceutical products, particularly RNA activating immunotherapeutics.
- Virend Platform: This drug platform focuses on novel TLR3 agonists and has potential for broad-spectrum use against multiple viruses and immune disorders.
Leadership and Structure
The leadership team consists of executives with experience in pharmaceuticals, biotechnology, and business development. The organizational structure includes departments for research and development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Virend Platform Drugs: Novel TLR3 agonists in development for potential use against multiple viruses and immune disorders. There is currently no Market Share or Revenue Data for this product as it is in trials. Competitors include companies developing antiviral therapies and immunomodulators.
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation in therapeutics and increasing demand for effective treatments of viral infections and immune disorders.
Positioning
Ainos Inc. aims to be a key player in RNA-based immunotherapeutics, focusing on developing innovative therapies.
Total Addressable Market (TAM)
The TAM for antiviral and immunomodulatory therapies is billions of dollars annually. Ainos Inc. is positioned to capture a portion of this market with its Virend platform.
Upturn SWOT Analysis
Strengths
- Novel drug platform (Virend)
- Focus on RNA-activating immunotherapeutics
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Relatively small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Successful clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Unsuccessful clinical trials
Competitors and Market Share
Key Competitors
- GILD
- MRNA
- VRTX
Competitive Landscape
Ainos Inc. faces competition from larger, more established pharmaceutical companies with greater resources and existing market presence. Its success depends on the differentiated value proposition of its RNA-activating immunotherapeutics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been marked by advancements in the development of its Virend platform.
Future Projections: Future growth depends on successful clinical trials and potential commercialization of its drug candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials and securing financing for R&D activities.
Summary
Ainos Inc. is a development-stage pharmaceutical company focused on innovative immunotherapeutics. Its novel Virend platform holds promise, but the company faces financial and regulatory hurdles. Successful clinical trials and strategic partnerships are crucial for future growth. The company must also be aware of the competition in the antiviral drug market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ainos Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-11-04 | CEO, President & Chairman of the Board Mr. Chun-Hsien Tsai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 44 | Website https://www.ainos.com |
Full time employees 44 | Website https://www.ainos.com | ||
Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics. Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data. The company is also giving AI for robotics, smart factories, senior care, and women's health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.